273 related articles for article (PubMed ID: 30421554)
1. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
Chouhan H; Sammour T; L Thomas M; W Moore J
Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
[TBL] [Abstract][Full Text] [Related]
2. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
5. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.
Taieb J; Sinicrope FA; Pederson L; Lonardi S; Alberts SR; George TJ; Yothers G; Van Cutsem E; Saltz L; Ogino S; Kerr R; Yoshino T; Goldberg RM; André T; Laurent-Puig P; Shi Q
Ann Oncol; 2023 Nov; 34(11):1025-1034. PubMed ID: 37619846
[TBL] [Abstract][Full Text] [Related]
6. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
[TBL] [Abstract][Full Text] [Related]
7. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
8. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
Bruzzi M; Auclin E; Lo Dico R; Voron T; Karoui M; Espin E; Cianchi F; Weitz J; Buggenhout A; Malafosse R; Denimal F; Le Malicot K; Vernerey D; Douard R; Emile JF; Lepage C; Laurent-Puig P; Taieb J
Ann Surg Oncol; 2019 Oct; 26(11):3561-3567. PubMed ID: 31209667
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS
Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
[TBL] [Abstract][Full Text] [Related]
11. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
[TBL] [Abstract][Full Text] [Related]
12. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
[TBL] [Abstract][Full Text] [Related]
14. Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status.
Patil DT; Shadrach BL; Rybicki LA; Leach BH; Pai RK
Mod Pathol; 2012 Oct; 25(10):1423-31. PubMed ID: 22684223
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in sporadic colon cancer with high-level microsatellite instability.
Oh BY; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
Surgery; 2016 May; 159(5):1372-81. PubMed ID: 26775578
[TBL] [Abstract][Full Text] [Related]
16. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
[TBL] [Abstract][Full Text] [Related]
17. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.
Fariña-Sarasqueta A; van Lijnschoten G; Moerland E; Creemers GJ; Lemmens VEPP; Rutten HJT; van den Brule AJC
Ann Oncol; 2010 Dec; 21(12):2396-2402. PubMed ID: 20501503
[TBL] [Abstract][Full Text] [Related]
18. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
